In 1949, Medtronic was founded by Earl Bakken and his brother-in-law Palmer Hermundslie in Minnesota, USA.Founded in a garage in Minneapolis。
At the beginning, Medtronic was just a workshop-style medical equipment repair shop. After 75 years of development, Medtronic has grown from a small workshop...Medtronic has developed into the world's largest medical device company, with nearly 100,000 employees in more than 150 countries and regions, a market value of over 100 billion US dollars, and sales exceeding 32.4 billion US dollars.
Medtronic’s transformation from a workshop-style small shop to the world's largest medical device company within 75 years can be attributed to the wise leadership of its seven CEOs. Despite their different styles, each CEO contributed to Medtronic’s unique growth in their own way. For example, Earl Bakken infused Medtronic with an innovative spirit, Winston Wallin introduced diversification, and Bill George embedded internationalization, among others. The diverse approaches of the different CEOs enriched Medtronic’s corporate culture, making it highly competitive.【01】Earl Bakken
1949-1985
Earl Bakken, the co-founder and first CEO of Medtronic, was a pioneer in medical technology. He transformed Medtronic from a repair shop into a multi-billion-dollar enterprise and laid the foundation for Medtronic's future in the medical device field.In 1957, Bakken invented the world's first battery-powered portable external pacemaker, which established Medtronic's innovative position in the medical device field and embedded the gene of innovation in Medtronic’s DNA.
Win Wallin became the CEO in 1991. He continued to implement the growth strategy, strengthened the company's global presence, and expanded its scale and influence in the medical device market.Propose a diversification strategy for products as the primary goal of their work.During his tenure, the company achieved equal success in both research and development and mergers and acquisitions.MedtronicThrough internal R&D and acquisitions, successfully transformed from a single-product company into a diversified, international medical technology company.The First Implantable Cardioverter DefibrillatorWorld's First SynchroMed Implantable and Programmable Drug Infusion SystemCapSure leads, with innovative steroid coatings, reduce inflammation of the myocardial tissue.Johnson & Johnson's Cardiovascular Division (Biological Heart Valves and Cardiopulmonary Devices)VersaflemMedical (Coronary Angiography Catheter and Guiding Technology)Bio-Medicus (Centrifugal Blood Pump)Bill George took over in 1991.Winston WallinServed as CEO. He led the company through a period of rapid growth and accelerated innovation, expanding into new markets. During his tenure, Medtronic became a truly global organization, valued at over $600 billion.BillRetired from the position of CEO in 2002.
Bill isOmar·Ishraq was the most successful CEO before. During his tenure, Medtronic's sales increased from less than 1 billion USD to 40 billion USD.Increase 4 times), the company's market value has grown from $5 billion to $65 billion (a 13-fold increase).
Bill not only consolidated Medtronic's traditional business but also launched treatmentsTremor and Parkinson's disease neuromodulators, as well as PCI-related products. Meanwhile, throughThe acquisition extends the business to various fields such as spinal and orthopedic surgery, peripheral vascular, external defibrillation, and otorhinolaryngology.
Art Collins became the CEO in 2002 after serving as president and chief operating officer. He led the company through a challenging period during whichMedtronic's sales grow at an annual compound growth rate of over 15%. MeanwhileHe also initiated Medtronic's true diversification strategy, completed acquisitions of multiple companies, and launched new businesses for Medtronic.InArthur Collins Kickstarts Diabetes, Spine, and Electrophysiology Businesses Through M&A:Acquired MiniMed for $3.7 billion in 2001In 2002$269 Million Acquisition of Cervical Disc Company SpinalDynamicsAcquired for $1.35 billion in 2005Spine Surgery Products Company Karlin Technology
In 2007, for $3.9 billionAcquisitionSpinal Surgery Products CompanyKyphon AmericasMarch 8, 2008Billion-dollar AcquisitionCryoCath TechnologiesBill Hawkins took over in 2008.Arthur Collins becameChief Executive Officer. He focuses on strengthening the company's core business. Hawkins took several major steps after taking office.After the acquisition, the focus was on integration and simplification of operations. Medtronic's business operations were restructured, merging Cardiac Rhythm Disease Management, Cardiovascular, and Electrophysiology into one operating unit, and combining Spine and Biologics, Neuromodulation, Diabetes, and Surgical Technologies into another operating unit. During Hawkins' tenure, the biggest issue he faced was the Sprint Fidelis lead recall., which was eventually resolved by paying $268 million.Omar IshrakAfter serving as President and CEO of GE Healthcare, he became the CEO of Medtronic in 2011.Omar transformed Medtronic into a truly global company, focusing on expanding healthcare services in new geographic regions and emphasizing value-based healthcare solutions.InDuring Omar's tenure, several major mergers and acquisitions were completed, the most significant of which was the acquisition of Covidien for $42.9 billion. This acquisition also stands as the largest merger and acquisition in the history of the medical device industry. The acquisition of Covidien also enabled Medtronic to surpass Johnson & Johnson to become the global leader in medical devices.Within 9 years, Medtronic's market value tripled, increasing from $51 billion to$150 billion, becoming the world's largest pure medical device company by market value.Omar can be said to be the greatest CEO in Medtronic's history.Retired in 2020, and afterwards...Served as the chairman of Intel.
Geoff Martha took over from Omar as the new CEO of Medtronic during the COVID-19 pandemic. He once pushed Medtronic's market value to a peak of 160 billion US dollars, but this market value seemed more like a continuation of the Omar era. Now, Medtronic's market value has dropped by 60 billion US dollars and has been surpassed by companies such as Stryker and Boston Scientific.At the same time, Medtronic also faces indigestion caused by Omar's large-scale mergers and acquisitions, and has begun to encounter various quality issues. Just between July 1, 2023, and June 30, 2024, Medtronic initiated 23 voluntary recalls. These included multiple Level 1 recalls, involving products such as the Duet External Drainage and Monitoring System, StealthStation S8 Platform software, Implantable Cardioverter Defibrillators (ICDs), and Cardiac Resynchronization Therapy Defibrillators (CRT-Ds), among others.Therefore, in the few years since Jeff Martha took office, Medtronic has significantly reduced the number of acquisitions and switched to a subtraction model - divesting its patient monitoring and respiratory intervention businesses. It is estimated that in the coming years...Jeff·MaSha Hui XiangHawkins,Focus on the wholeStreamlining operations allows Medtronic to digestLegacy issues during Omar's period of great development.
